^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    Tecentriq (atezolizumab)

    i
    Other names: MPDL3280A, RG7446, RO5541267, MPDL-3280A, RG-7446, RO 5541267, RO 554-1267, RG7446-42, RO-5541267, MPDL 3280A, RG 7446, RG744642, RG 744642, RG-744642, RO-5541267 IV, MPDL 3280A IV
    Company:
    Roche
    Drug class:
    PD-L1 inhibitor
    Related drugs:
    12h
    A Study to Evaluate Safety and Anti-Tumor Activity of Eciskafusp Alfa (RO7284755) Alone or in Combination With Atezolizumab in Participants With Advanced and/or Metastatic Solid Tumors (clinicaltrials.gov)
    P1, N=189, Completed, Hoffmann-La Roche | Active, not recruiting --> Completed | Trial completion date: Aug 2026 --> Oct 2025 | Trial primary completion date: Jan 2026 --> Oct 2025
    Trial completion • Trial completion date • Trial primary completion date • Tumor mutational burden • IO biomarker
    |
    PD-L1 (Programmed death ligand 1)
    |
    Tecentriq (atezolizumab) • eciskafusp alfa (RG6279)
    20h
    Phenix: Efficacy of the Combination of Trimipramine and Atezolizumab With Bevacizumab in Patients With Recurrent Glioblastoma: a Phase 2 Trial (clinicaltrials.gov)
    P2, N=59, Recruiting, Centre Hospitalier Universitaire Vaudois
    New P2 trial
    |
    Avastin (bevacizumab) • Tecentriq (atezolizumab)
    1d
    NRG-LU005: Testing the Addition of a New Immunotherapy Drug, Atezolizumab (MPDL3280A), to the Usual Chemoradiation (CRT) Therapy Treatment for Limited Stage Small Cell Lung Cancer (LS-SCLC) (clinicaltrials.gov)
    P3, N=544, Active, not recruiting, National Cancer Institute (NCI) | Trial completion date: Feb 2026 --> Feb 2029
    Trial completion date
    |
    cisplatin • Tecentriq (atezolizumab) • carboplatin • etoposide IV
    1d
    Efficacy and safety of atezolizumab plus bevacizumab in MSI-like metastatic colorectal cancer: a multicenter, single-arm, phase II, open-label clinical trial. (PubMed, ESMO Open)
    MSI-like GES does not identify a population with higher sensitivity to immune checkpoint plus angiogenesis inhibition. However, responses are promising in patients with MSI tumors and, to a lesser extent, in patients without liver metastasis regardless of MSI status.
    P2 data • Journal • PD(L)-1 Biomarker • IO biomarker
    |
    MSI (Microsatellite instability)
    |
    Avastin (bevacizumab) • Tecentriq (atezolizumab)
    2d
    PD-L1 PET-imaging During CAR T-cell Therapy (clinicaltrials.gov)
    P2, N=20, Active, not recruiting, University Medical Center Groningen | Recruiting --> Active, not recruiting | Trial primary completion date: Apr 2025 --> Dec 2025
    Enrollment closed • Trial primary completion date • IO biomarker
    |
    PD-L1 (Programmed death ligand 1)
    |
    Tecentriq (atezolizumab)
    2d
    Atezolizumab With Bevacizumab and Nonplatinum Chemotherapy for Recurrent Ovarian Cancer: Final Results From the Placebo-Controlled AGO-OVAR 2.29/ENGOT-ov34 Phase III Trial. (PubMed, J Clin Oncol)
    Combining atezolizumab with bevacizumab and chemotherapy did not significantly improve OS or PFS in patients with recurrent ovarian cancer ineligible for platinum. The safety profile was as expected from previous experience with these drugs.
    P3 data • Journal
    |
    PD-L1 expression
    |
    VENTANA PD-L1 (SP142) Assay
    |
    Avastin (bevacizumab) • Tecentriq (atezolizumab) • paclitaxel • pegylated liposomal doxorubicin
    2d
    Atezolizumab + Cabozantinib in Patients w/ Metastatic, Refractory Pancreatic Cancer (clinicaltrials.gov)
    P2, N=29, Recruiting, University of Arizona | Trial completion date: Oct 2025 --> Jan 2026 | Trial primary completion date: Oct 2025 --> Jan 2026
    Trial completion date • Trial primary completion date
    |
    Tecentriq (atezolizumab) • Cabometyx (cabozantinib tablet)
    4d
    BIS-Program: Impact of Neoadjuvant Immunotherapy in Early Stage Breast Cancer Before Standard Therapy (clinicaltrials.gov)
    P2, N=33, Terminated, Gustave Roussy, Cancer Campus, Grand Paris | N=185 --> 33 | Trial completion date: Feb 2026 --> Dec 2024 | Recruiting --> Terminated; Abandon of the partner, ROCHE
    Enrollment change • Trial completion date • Trial termination • IO biomarker
    |
    HER-2 (Human epidermal growth factor receptor 2) • PD-L1 (Programmed death ligand 1) • PGR (Progesterone receptor)
    |
    HER-2 positive • HER-2 overexpression • HER-2 amplification • HER-2 positive + HER-2 overexpression
    |
    Avastin (bevacizumab) • Herceptin (trastuzumab) • Tecentriq (atezolizumab) • Perjeta (pertuzumab)
    4d
    ARIANES: Efficacy and Safety of the Combination of Rucaparib (PARP Inhibitor) and Atezolizumab (Anti-PD-L1 Antibody) in Patients With DNA Repair-deficient or Platinum-sensitive Solid Tumors (clinicaltrials.gov)
    P2, N=130, Terminated, Gustave Roussy, Cancer Campus, Grand Paris | Suspended --> Terminated; Bankruptcy of partner: Clovis
    Trial termination • Pan tumor • Platinum sensitive
    |
    BRCA1 (Breast cancer 1, early onset) • BRCA2 (Breast cancer 2, early onset) • ATM (ATM serine/threonine kinase) • CDK12 (Cyclin dependent kinase 12) • CHEK2 (Checkpoint kinase 2) • RAD51 (RAD51 Homolog A) • FANCA (FA Complementation Group A) • BRIP1 (BRCA1 Interacting Protein C-terminal Helicase 1) • RAD51C (RAD51 paralog C) • IL2 (Interleukin 2) • RAD51D (RAD51 paralog D) • BARD1 (BRCA1 Associated RING Domain 1) • NBN (Nibrin Nijmegen Breakage Syndrome 1 (Nibrin)) • RAD54L (DNA Repair And Recombination Protein RAD54) • DRD (DNA Repair Deficiency)
    |
    DDR • CDK12 mutation • CHEK2 mutation • BRIP1 mutation • RAD51C mutation • RAD51D mutation • BARD1 mutation
    |
    Tecentriq (atezolizumab) • Rubraca (rucaparib)
    4d
    Lenvatinib vs. sorafenib as second-line treatment post atezolizumab plus bevacizumab for hepatocellular carcinoma: The LEVIATHAN study. (PubMed, JHEP Rep)
    These results challenge the assumption that all VEGFR-targeting TKIs are equivalent post-ICI and suggest lenvatinib may be superior to sorafenib following anti-VEGF-based immunotherapy. While prospective randomised trials are still needed, these real-world data offer valuable guidance for clinicians and help refine treatment sequencing in advanced HCC.
    Journal
    |
    AFP (Alpha-fetoprotein)
    |
    Avastin (bevacizumab) • Tecentriq (atezolizumab) • sorafenib • Lenvima (lenvatinib)
    6d
    Molecular subtypes of hepatocellular carcinoma linked to liver cell lineages and clinical outcomes of combination immunotherapy. (PubMed, Cell Rep Med)
    These subtypes showed distinct tumor cell-intrinsic and extrinsic features, including different immune contextures, and importantly an association with clinical response to atezolizumab plus bevacizumab combination immunotherapy. In a humanized HCC xenograft mouse model recapitulating the GPC3-high progenitor-like subtype, a GPC3/CD3 bispecific antibody elicited strong antitumor activity mediated by intratumoral recruitment and activation of T cells. Our study provides biological insights into HCC heterogeneity and potential strategies for targeting subtype-specific vulnerabilities.
    Clinical data • Preclinical • Journal
    |
    GPC3 (Glypican 3)
    |
    Avastin (bevacizumab) • Tecentriq (atezolizumab)
    7d
    Morpheus-TNBC: A Study Evaluating the Efficacy and Safety of Multiple Treatment Combinations in Patients With Metastatic or Locally Advanced Breast Cancer (clinicaltrials.gov)
    P1/2, N=792, Recruiting, Hoffmann-La Roche | N=580 --> 792 | Trial completion date: May 2028 --> Sep 2030 | Trial primary completion date: May 2028 --> Sep 2030
    Enrollment change • Trial completion date • Trial primary completion date
    |
    HER-2 (Human epidermal growth factor receptor 2) • PD-L1 (Programmed death ligand 1) • PIK3CA (Phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha)
    |
    PD-L1 expression • PIK3CA mutation
    |
    VENTANA PD-L1 (SP142) Assay
    |
    Avastin (bevacizumab) • Tecentriq (atezolizumab) • Ibrance (palbociclib) • carboplatin • gemcitabine • Enhertu (fam-trastuzumab deruxtecan-nxki) • capecitabine • Verzenio (abemaciclib) • albumin-bound paclitaxel • Kisqali (ribociclib) • fulvestrant • Halaven (eribulin mesylate) • letrozole • ipatasertib (RG7440) • Trodelvy (sacituzumab govitecan-hziy) • Itovebi (inavolisib) • Actemra IV (tocilizumab) • atirmociclib (PF-07220060) • ladiratuzumab vedotin (SGN-LIV1A) • selicrelumab (RG7876)